{"id":"anastrozole-tablets","safety":{"commonSideEffects":[{"rate":"36","effect":"Hot flashes"},{"rate":"15-26","effect":"Arthralgia/joint pain"},{"rate":"17-19","effect":"Fatigue"},{"rate":"7-8","effect":"Headache"},{"rate":"2-5","effect":"Vaginal dryness"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":{"chemblId":"CHEMBL1399","moleculeType":"Small molecule","molecularWeight":"293.37"},"_dailymed":{"setId":"7b3da447-8e7c-2aaa-e053-2a91aa0a2821","title":"ANASTROZOLE (ANASTROZOLE TABLETS) TABLET [YILING PHARMACEUTICAL, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anastrozole is a non-steroidal aromatase inhibitor that selectively blocks aromatase, the key enzyme responsible for estrogen synthesis in postmenopausal women. By reducing estrogen levels, it deprives estrogen receptor-positive breast cancer cells of the hormone signals needed for growth and proliferation. This mechanism is particularly effective in hormone-dependent breast cancers where estrogen drives tumor progression.","oneSentence":"Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:36.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women"},{"name":"First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women"},{"name":"Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT05524584","phase":"PHASE2","title":"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-31","conditions":"Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":20},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT01953588","phase":"PHASE3","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-02-27","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma","enrollment":1473},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT00984399","phase":"NA","title":"Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09-22","conditions":"Atrophic Vaginitis, Breast Cancer","enrollment":31},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT04711252","phase":"PHASE3","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":1370},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT05549505","phase":"PHASE2","title":"A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery","status":"COMPLETED","sponsor":"Arvinas Inc.","startDate":"2023-02-15","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT03490513","phase":"PHASE4","title":"Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-04-15","conditions":"Hypogonadism, Hypogonadotropic, Obesity","enrollment":121},{"nctId":"NCT03909152","phase":"PHASE2","title":"A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-02","conditions":"Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer","enrollment":34},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT05257395","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-03-14","conditions":"Advanced Breast Cancer","enrollment":397},{"nctId":"NCT06953882","phase":"PHASE2","title":"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-07-09","conditions":"HER2 Negative Breast Cancer","enrollment":140},{"nctId":"NCT03099174","phase":"PHASE1","title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-04","conditions":"Neoplasms, Breast Neoplasms","enrollment":133},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT04985266","phase":"PHASE2","title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-03-30","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer","enrollment":1100},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT02758431","phase":"NA","title":"Cardiovascular Outcomes of Low Testosterone","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-07-01","conditions":"Hypogonadism","enrollment":232},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT06341283","phase":"","title":"A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-06-01","conditions":"Breast Cancer, Neoplasms, Breast Diseases","enrollment":200},{"nctId":"NCT03229499","phase":"PHASE2","title":"Pulmonary Hypertension and Anastrozole Trial","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-12-07","conditions":"Pulmonary Arterial Hypertension","enrollment":84},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT02730923","phase":"PHASE1, PHASE2","title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2016-04","conditions":"Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor","enrollment":72},{"nctId":"NCT06235931","phase":"NA","title":"A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Breast Neoplasms","enrollment":34},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT02585388","phase":"PHASE2","title":"Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.","status":"TERMINATED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-10-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT03555877","phase":"PHASE2","title":"Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-15","conditions":"Breast Cancer Metastatic","enrollment":56},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05792410","phase":"PHASE1, PHASE2","title":"A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04","conditions":"HER2 Low Advanced or Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT02894398","phase":"PHASE2","title":"Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-09-06","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":388},{"nctId":"NCT00543127","phase":"PHASE3","title":"Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2007-11","conditions":"Breast Cancer","enrollment":870},{"nctId":"NCT00828854","phase":"PHASE2","title":"Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-10-01","conditions":"ER+ Breast Cancer","enrollment":27},{"nctId":"NCT04666961","phase":"PHASE2","title":"Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2021-02-03","conditions":"Ductal Carcinoma in Situ, Extensive Disease, Mastectomy","enrollment":262},{"nctId":"NCT05167643","phase":"NA","title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-23","conditions":"Advanced HR+ HER2 Negative Breast Carcinoma","enrollment":40},{"nctId":"NCT02213042","phase":"PHASE2","title":"Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10-24","conditions":"Neoplasms, Breast","enrollment":42},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00688909","phase":"PHASE4","title":"Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Breast Cancer","enrollment":261},{"nctId":"NCT03966898","phase":"PHASE3","title":"A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-19","conditions":"Advanced Breast Cancer","enrollment":426},{"nctId":"NCT04757532","phase":"PHASE1","title":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-12-03","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000},{"nctId":"NCT01231659","phase":"PHASE2","title":"Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-09","conditions":"Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT01783444","phase":"PHASE2","title":"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-26","conditions":"Breast Cancer","enrollment":309},{"nctId":"NCT00871858","phase":"PHASE2","title":"Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-03-18","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT04666805","phase":"","title":"Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2020-07-01","conditions":"Breast Cancer","enrollment":1354},{"nctId":"NCT02511639","phase":"PHASE3","title":"Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2014-07-30","conditions":"Breast Cancer Metastatic","enrollment":110},{"nctId":"NCT04619914","phase":"NA","title":"the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women","status":"COMPLETED","sponsor":"Laylay Mohammed Khalleefah Alhibshi","startDate":"2019-03-01","conditions":"Endometrial Thickness, Pregnancy Rate","enrollment":160},{"nctId":"NCT01466972","phase":"PHASE2","title":"Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib","status":"COMPLETED","sponsor":"Hope Rugo, MD","startDate":"2012-04-27","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT04438733","phase":"PHASE1","title":"Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-06-18","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT04445922","phase":"PHASE1","title":"Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-07-04","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT00295620","phase":"PHASE3","title":"Secondary Adjuvant Long Term Study With Arimidex","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-03-01","conditions":"Breast Cancer","enrollment":3484},{"nctId":"NCT02093351","phase":"PHASE1","title":"To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-01","conditions":"Solid Tumours","enrollment":79},{"nctId":"NCT00274469","phase":"PHASE2","title":"A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-02-06","conditions":"Metastatic Breast Cancer","enrollment":205},{"nctId":"NCT03024580","phase":"PHASE2","title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-03-06","conditions":"Breast Neoplasm","enrollment":20},{"nctId":"NCT00179517","phase":"PHASE2","title":"Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-06","conditions":"Seizure Disorder, Hypogonadism, Erectile Dysfunction","enrollment":40},{"nctId":"NCT01597193","phase":"PHASE1","title":"Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04-30","conditions":"Breast Cancer","enrollment":101},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT01381874","phase":"PHASE2","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-24","conditions":"Metastatic ER+ Her2- Breast Cancer, Postmenopausal","enrollment":297},{"nctId":"NCT00104572","phase":"PHASE2","title":"Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2004-03","conditions":"Hypogonadism, Diabetes, Sarcopenia","enrollment":44},{"nctId":"NCT02689921","phase":"PHASE2","title":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","status":"UNKNOWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-04","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT03081234","phase":"PHASE3","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01155102","phase":"NA","title":"Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2006-04","conditions":"Breast Cancer","enrollment":31},{"nctId":"NCT01155089","phase":"NA","title":"Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2006-05","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT00863655","phase":"PHASE3","title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-03","conditions":"Breast Cancer","enrollment":724},{"nctId":"NCT03118479","phase":"PHASE1","title":"Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2010-05","conditions":"Hypogonadotropic Hypogonadism, Kallmann Syndrome","enrollment":7},{"nctId":"NCT01626222","phase":"PHASE3","title":"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":301},{"nctId":"NCT01545336","phase":"PHASE2","title":"Anastrozole in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-10","conditions":"Pulmonary Arterial Hypertension","enrollment":18},{"nctId":"NCT01520467","phase":"NA","title":"Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Silver Russell Syndrome, Prader-Willi Syndrome","enrollment":27},{"nctId":"NCT00248170","phase":"PHASE3","title":"Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Breast Cancer","enrollment":4172},{"nctId":"NCT01972984","phase":"PHASE2","title":"Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2012-10","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT01151215","phase":"PHASE2","title":"Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Neoplasms, Breast Neoplasms, Breast Cancer","enrollment":482},{"nctId":"NCT00077025","phase":"PHASE2","title":"Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-01","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT00555477","phase":"PHASE2","title":"Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-08","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT00354640","phase":"PHASE2","title":"Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-06","conditions":"Breast Cancer","enrollment":11},{"nctId":"NCT00022672","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-01","conditions":"Breast Cancer","enrollment":208},{"nctId":"NCT00122356","phase":"PHASE3","title":"Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment","status":"COMPLETED","sponsor":"Barwon Health","startDate":"2005-09","conditions":"Breast Cancer","enrollment":303},{"nctId":"NCT00259090","phase":"PHASE2","title":"Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00256698","phase":"PHASE3","title":"Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-01","conditions":"Breast Cancer","enrollment":514},{"nctId":"NCT01568281","phase":"PHASE1","title":"Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Safety, Pharmacokinetics","enrollment":58},{"nctId":"NCT00935558","phase":"PHASE2","title":"Dendritic Cell Based Therapy for Breast Cancer Patients","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00437359","phase":"PHASE2","title":"Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer","status":"TERMINATED","sponsor":"Japan Breast Cancer Research Network","startDate":"2007-05","conditions":"Breast Neoplasms","enrollment":240},{"nctId":"NCT00143390","phase":"PHASE3","title":"Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-04","conditions":"Breast Neoplasms","enrollment":298},{"nctId":"NCT00944918","phase":"PHASE3","title":"Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Progression-free Survival","enrollment":25},{"nctId":"NCT00327769","phase":"PHASE3","title":"Faslodex Advanced Breast Cancer Local Chinese Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Advanced Breast Cancer","enrollment":234},{"nctId":"NCT00357110","phase":"PHASE2","title":"Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Breast Cancer","enrollment":13}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"ARTHRALGIA"},{"count":3,"reaction":"ANXIETY"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"NAUSEA"},{"count":2,"reaction":"DEPRESSION"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":2,"reaction":"MOOD ALTERED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anastrozole Tablets","genericName":"Anastrozole Tablets","companyName":"Tolmar Inc.","companyId":"tolmar-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anastrozole inhibits the enzyme aromatase, which converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels to treat hormone receptor-positive breast cancer. Used for Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, First-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women, Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}